An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202.
Vogel A, Sahai V, Hollebecque A, Vaccaro GM, Melisi D, Al Rajabi RM, Paulson AS, Borad MJ, Gallinson D, Murphy AG, Oh DY, Dotan E, Catenacci DV, Van Cutsem E, Lihou CF, Zhen H, Veronese ML, Abou-Alfa GK.
Vogel A, et al. Among authors: murphy ag.
ESMO Open. 2024 Jun 4;9(6):103488. doi: 10.1016/j.esmoop.2024.103488. Online ahead of print.
ESMO Open. 2024.
PMID: 38838500
Free article.